Murali Janakiram

16PUBLICATIONS
135CO-AUTHORS
Haematological tumoursCardiology (incl. cardiovascular diseases)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 02, 2026
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

|Jun 29, 2026
Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy.

|Jun 12, 2026
Counterpoint: Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma.

|May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.

|Nov 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Richard T Maziarz, Michael R Bishop, Constantine S Tam

|Jul 25, 2025
CNS Involvement by North American-Adult T-cell Leukemia/Lymphoma Is Associated With Discrete Dissemination Patterns and Molecular Profiles, Involving XPO1 E571 and KLF2/PI3KCD in Selected Cases.

Nishi Shah, Melissa Suchanek, Astha Thakkar

Pageof 3

Frequent Collaborators

3 joint publications

Urvi Shah

3 joint publications

Danai Dima

3 joint publications

B Hilda Ye

3 joint publications

Ana Acuna-Villaorduna